Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 17/20 | 0.86 |
| ▸ | MTNR1B | P49286 | 15/20 | 0.86 |
| ▸ | NQO2 | P16083 | 14/20 | 0.86 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7950130 | 1.00 | MTNR1A (0.86) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL7952490 | 0.93 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL4685396 | 0.93 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL7950293 | 0.93 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL4685402 | 0.93 | MTNR1A (1.00) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL7956065 | 0.92 | MTNR1A (0.73) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL8889850 | 0.89 | MTNR1A (0.72) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL7017326 | 0.88 | MTNR1A (0.75) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL7952293 | 0.88 | MTNR1A (0.74) | MTNR1AMTNR1BNQO2TRPV1 | |
| SCHEMBL8887234 | 0.88 | MTNR1A (0.87) | MTNR1AMTNR1BNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5661186-A | MELATONERGIC EFFECT; CENTRAL NERVOUS SYSTEM DISODERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | claimed |
| EP-0728738-A1 | Tetralinyl- and indanyl-ethylamides having melatonergic activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-28 | — | — | EP | claimed |
| EP-3077354-B1 | NOVEL METHOD FOR THE SYNTHESIS OF AGOMELATINE | SERVIER LAB (FR) | 2017-11-29 | — | — | EP | disclosed |
| CN-104016874-A | N-[2-(7-methoxy-1,2,3,4-tetrahydro-1-naphthyl)-ethyl]-acetamide as well as preparation method and application thereof | HEFEIYANG TECHNOLOGY DEV TIANJIN CO LTD | 2014-09-03 | — | — | CN | disclosed |
| CN-104016874-A | N-[2-(7-methoxy-1,2,3,4-tetrahydro-1-naphthyl)-ethyl]-acetamide as well as preparation method and application thereof | HEFEIYANG TECHNOLOGY DEV TIANJIN CO LTD | 2014-09-03 | — | — | CN | disclosed |
| EP-2580183-B1 | NEW PROCESS FOR THE PREPARATION OF N-[2-(7-METHOXY-1-NAPHTHYL)-ETHYL]ACETAMIDE | GADOR SA (AR) | 2014-07-23 | — | — | EP | disclosed |
| EP-2580183-B1 | NEW PROCESS FOR THE PREPARATION OF N-[2-(7-METHOXY-1-NAPHTHYL)-ETHYL]ACETAMIDE | GADOR SA (AR) | 2014-07-23 | — | — | EP | disclosed |
| US-8779199-B2 | Agomelatine intermediates and preparation method thereof | LES LABORATOIRES SERVIER (FR) | 2014-07-15 | — | — | US | disclosed |
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | LES LABORATORIES SERVIER (FR) | 2013-10-10 | — | — | US | disclosed |
| EP-2580183-A2 | NEW PROCESS FOR THE PREPARATION OF N-[2-(7-METHOXY-1-NAPHTHYL)-ETHYL]ACETAMIDE AND NEW CRYSTALLINE FORM | GADOR S.A. (AR) | 2013-04-17 | — | — | EP | disclosed |
| WO-2011154140-A2 | NEW PROCESS FOR THE PREPARATION OF N-[2-(7-METHOXY-1-NAPHTHYL)-ETHYL]ACETAMIDE AND NEW CRYSTALLINE FORM | GADOR S.A. (AR) | 2011-12-15 | — | — | WO | disclosed |
| US-20020035114-A1 | Substituted dimeric compounds | LESIEUR DANIEL (FR) | 2002-03-21 | — | — | US | disclosed |
| US-6319930-B1 | CONTAINING FUSED AROMATIC CARBO- OR HETEROCYCLIC RINGS AND AMIDE, THIOAMIDE, UREA OR THIOUREA GROUPS; USEFUL IN TREATING OR IN PREVENTING MELATONINERGIC DISORDERS. | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | disclosed |
| US-6235789-B1 | GLANDULAR DISORDERS; SLEEP DISORDERS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| EP-1038863-A2 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | ADIR ET COMPAGNIE (FR) | 2000-09-27 | — | — | EP | disclosed |
| EP-0781271-B1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-06-07 | — | — | EP | disclosed |
| US-5661186-A | MELATONERGIC EFFECT; CENTRAL NERVOUS SYSTEM DISODERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0781271-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-07-02 | — | — | EP | disclosed |
| EP-0728738-A1 | Tetralinyl- and indanyl-ethylamides having melatonergic activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1996008466-A1 | BENZOCYCLOALKENE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267738-A1 | AGOMELATINE INTERMEDIATES AND PREPARATION METHOD THEREOF | COMT, AGO2, MC5R | MTNR1A 9/4885MTNR1B 11/4885NQO2 3451/4885 |
| US-20020035114-A1 | Substituted dimeric compounds | NR0B2, NR0B1, NR2C2 | MTNR1A 4/4885MTNR1B 5/4885NQO2 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.